Loading
A phase 1/2 trial of Gemcitabine, CAPOX, Cyclophosphamide in diffuse large b-cell lymphoma, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma is a phase 1/2 interventional study registered as NCT07124936 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 97 participants planned, started 2025-07-30 and due to reach its primary completion in 2027-10-26. Interventions recorded: HDM2005, Rituximab or Rituximab biosimilar, Gemcitabine, Oxaliplatin, Cyclophosphamide. Conditions listed: Diffuse Large B Cell Lymphoma (DLBCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/